Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 83
- 试验地点
- 1
- 主要终点
- Complete remission
研究概览
简要总结
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About 60-70% of patients achieved complete remission after this standard chemotherapy. As cytarabine competes with endogenous nucleotides to exert its activity, the aim of this protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of the induction treatment. Thus, intracellular nucleotides levels will be determined in peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment, and results will be compared with the efficacy of the treatment. This parameter will be assessed by the achievement of complete remission.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •age over 18 years
- •acute myeloid leukemia
- •standard induction chemotherapy with cytarabine and daunorubicin
- •patients who received the information and did not object to participate to the study
排除标准
- •patients with acute myeloid leukemia 3
- •healthy volunteers Inclusion Criteria :
- •adults without known hematological disease,
- •adults who received the information and did not object to participate in the study
- •healthy volunteers Exclusion Criteria :
- •Volunteers with known hematological disease.
结局指标
主要结局
Complete remission
时间窗: 30 days
Primary endpoint will be the achievement of complete remission after induction treatment and bone marrow aplasia.
次要结局
未报告次要终点